I-Chen Huang

I-Chen Huang

Auto-generated profile, based on publicly available information

I-Chen Huang

Department of Neurology, Wan Fang Hospital, Taipei Medical University , Taipei , Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2022 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
IHI-Chen Huang
I-Chen Huang
TCTsui-San Chang
Tsui-San Chang
CCChiehfeng Chen
Chiehfeng Chen
JSJia-Ying Sung
Jia-Ying Sung
Background: Dementia and depression are increasingly common worldwide, and their effective control could ease the burden on economies, public health systems, and support networks. Vortioxetine is a new antidepressant with multipharmacologic actions that elevate the concentration of serotonin and modulate multiple neurotransmitter receptors in the brain. We conducted a meta-analysis to explore whether the cognitive function of patients with major depressive disorder (MDD) treated with vortioxetine would improve. Methods: We systematically reviewed randomized controlled trials (RCTs) in the PubMed, Embase, and Cochrane databases to assess the treatment effects of vortioxetine on the cognitive function of patients with MDD. The outcome measures included the Digit Symbol Substitution Test (DSST), Perceived Deficits Questionnaire (PDQ), and Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Pooled results were calculated using a fixed-effects or random-effects model according to the heterogeneity of the included trials. Results: Six RCTs with a total of 1782 patients were included in the meta-analysis, which demonstrated that vortioxetine improved DSST, PDQ, and MADRS scores in patients with MDD. The results were consistent at the 10- and 20-mg doses. In the 20-mg group, the decrease in MADRS scores was more significant than that in the placebo group. Conclusions: Both the 10- and 20-mg doses of vortioxetine can significantly increase DSST scores and decrease PDQ and MADRS scores in patients with MDD and cognitive dysfunction, but further studies with longer follow-up periods to assess mental function are required.

2 September 2026 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
CYChih-Hao Yang
Chih-Hao Yang
EKEnoch Yi-No Kang
Enoch Yi-No Kang
SHShih-Chang Hsu
Shih-Chang Hsu
SHSheng-Lun Hsu
Sheng-Lun Hsu
CHChin-Wang Hsu
Chin-Wang Hsu
IHI-Chen Huang
I-Chen Huang